Titre :

Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.

Auteur(s) :

Letarouilly, Jean-Guillaume [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Flachaire, Benoît [Auteur]
Aix Marseille Université [AMU]
Labadie, Céline [Auteur]
Université de Bordeaux [UB]
Kyheng, MaÉva [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Cohen, Nicolas [Auteur]
Aix Marseille Université [AMU]
Sellam, Jérémie [Auteur]
Centre de Recherche Saint-Antoine [UMRS893]
Richette, Pascal [Auteur]
Biologie de l'Os et du Cartilage : Régulations et Ciblages Thérapeutiques [BIOSCAR (UMR_S_1132 / U1132)]
Dieude, Philippe [Auteur]
Physiopathologie et Epidémiologie des Maladies Respiratoires [PHERE (UMR_S_1152 / U1152)]
Claudepierre, Pascal [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Fautrel, Bruno [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Houvenagel, Eric [Auteur]
Institut Catholique de Lille [ICL]
Nguyen, Chi Duc [Auteur]
Guyot, Marie-Hélène [Auteur]
Hôpital Victor Provo [Roubaix]
Segaud, Nicolas [Auteur]
Marguerie, Laurent [Auteur]
Institut Calot [Fondation Hopale]
Deprez, Xavier [Auteur]
Centre hospitalier [Valenciennes, Nord]
Salmon, Jean-Hugues [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Baudens, Guy [Auteur]
Centre hospitalier [Valenciennes, Nord]
Miceli-Richard, Corinne [Auteur]
Hôpital Cochin [AP-HP]
Gervais, Elisabeth [Auteur]
Service de rhumatologie [Poitiers]
Chary-Valckenaere, Isabelle [Auteur]
Service de Rhumatologie [CHRU Nancy]
Lafforgue, Pierre [Auteur]
Aix Marseille Université [AMU]
Philippe, Peggy [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Loeuille, Damien [Auteur]
Université de Poitiers = University of Poitiers [UP]
Richez, Christophe [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Tubach, Florence [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Pham, Thao [Auteur]
Aix Marseille Université [AMU]
Flipo, René-Marc [Auteur]
Service de rhumatologie[Lille]

Titre de la revue :

Rheumatology

Nom court de la revue :

Rheumatology (Oxford)

Numéro :

60

Pagination :

2773–2782

Date de publication :

2020-11-29

ISSN :

1462-0332

Mot(s)-clé(s) en anglais :

psoriatic arthritis
real-world
ustekinumab
secukinumab
persistence

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Methods In this retrospective, ...
Lire la suite >Objectives To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Methods In this retrospective, national, multicentre cohort study, pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥6 months were included from January 2011 to April 2019. The persistence between SEK and UST was assessed after considering the potential confounding factors by using pre-specified propensity-score methods. Causes of discontinuation and tolerance were also collected. Results A total of 406 pts were included: 245 with UST and 161 with SEK. The persistence rate was lower in the UST group compared with the SEK group [median persistence 9.4 vs 14.7 months; 26.4% vs 38.0% at 2 years; weighted hazard ratio (HR) = 1.42; 95% CI: 1.07, 1.92; P =0.015]. In subgroup analysis, the persistence rate of SEK associated with MTX was significantly higher than that of UST associated with MTX: HR = 2.20; 95% CI: 1.30, 3.51; P =0.001, in contrast to SEK vs UST monotherapy: HR = 1.06; 95% CI: 0.74, 1.53; P =0.75. Discontinuation due to inefficacy was reported in 91.7% (SEK) and 82.4% (UST) of pts. Discontinuation due to an adverse event was reported in 12.2% (SEK) and 7.7% (UST) of pts. Conclusion In this first study comparing UST and SEK, the persistence of SEK was higher than that of UST in PsA. In subgroup analysis, this difference was only found in association with MTX.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T07:44:54Z
2024-01-10T09:07:03Z
2024-01-10T09:09:26Z